Antibody data
- Antibody Data
- Antigen structure
- References [4]
- Comments [0]
- Validations [0]
Submit
Validation data
Reference
Comment
Report error
- Product number
- HPA054291 - Provider product page
- Provider
- Atlas Antibodies
- Proper citation
- Atlas Antibodies Cat#HPA054291, RRID:AB_2682438
- Product name
- Anti-MYSM1
- Antibody type
- Polyclonal
- Reactivity
- Human
- Host
- Rabbit
- Conjugate
- Unconjugated
- Antigen sequence
KQDETLSSSEITLWTEKQSNGDKKSIELNDQKFNE
LIKNCNKHDGRGIIVDARQLPSPEPCEIQKNLNDN
EMLFHSCQMVEESHEEEELK- Isotype
- IgG
- Vial size
- 100 µl
- Storage
- Store at +4°C for short term storage. Long time storage is recommended at -20°C.
Submitted references MYSM1 acts as a novel co-activator of ERα to confer antiestrogen resistance in breast cancer
MYSM1 inhibits human colorectal cancer tumorigenesis by activating miR-200 family members/CDH1 and blocking PI3K/AKT signaling
Interaction of Deubiquitinase 2A-DUB/MYSM1 with DNA Repair and Replication Factors.
MYSM1/2A-DUB is an epigenetic regulator in human melanoma and contributes to tumor cell growth
Luan R, He M, Li H, Bai Y, Wang A, Sun G, Zhou B, Wang M, Wang C, Wang S, Zeng K, Feng J, Lin L, Wei Y, Kato S, Zhang Q, Zhao Y
EMBO Molecular Medicine 2023;16(1):10-39
EMBO Molecular Medicine 2023;16(1):10-39
MYSM1 inhibits human colorectal cancer tumorigenesis by activating miR-200 family members/CDH1 and blocking PI3K/AKT signaling
Chen X, Wang W, Li Y, Huo Y, Zhang H, Feng F, Xi W, Zhang T, Gao J, Yang F, Chen S, Yang A, Wang T
Journal of Experimental & Clinical Cancer Research 2021;40(1)
Journal of Experimental & Clinical Cancer Research 2021;40(1)
Interaction of Deubiquitinase 2A-DUB/MYSM1 with DNA Repair and Replication Factors.
Kroeger C, Roesler R, Wiese S, Hainzl A, Gatzka MV
International journal of molecular sciences 2020 May 26;21(11)
International journal of molecular sciences 2020 May 26;21(11)
MYSM1/2A-DUB is an epigenetic regulator in human melanoma and contributes to tumor cell growth
Wilms C, Kroeger C, Hainzl A, Banik I, Bruno C, Krikki I, Farsam V, Wlaschek M, Gatzka M
Oncotarget 2017;8(40):67287-67299
Oncotarget 2017;8(40):67287-67299
No comments: Submit comment
No validations: Submit validation data